Eesti - eesti - Ravimiamet

teva b.v. - metformiin+vildagliptiin - õhukese polümeerikattega tablett - 850mg+50mg 12tk; 850mg+50mg 60tk; 850mg+50mg 30tk

Eesti - eesti - Ravimiamet

teva b.v. - metformiin+vildagliptiin - õhukese polümeerikattega tablett - 1000mg+50mg 12tk; 1000mg+50mg 60tk

Eesti - eesti - Ravimiamet

sia elvim - metformiin+vildagliptiin - õhukese polümeerikattega tablett - 1000mg+50mg 60tk

Eesti - eesti - Ravimiamet

sia elvim - metformiin+vildagliptiin - õhukese polümeerikattega tablett - 850mg+50mg 60tk

Eesti - eesti - Ravimiamet

sanoswiss uab - metformiin+vildagliptiin - õhukese polümeerikattega tablett - 1000mg+50mg 30tk; 1000mg+50mg 120tk; 1000mg+50mg 56tk; 1000mg+50mg 180tk

Eesti - eesti - Ravimiamet

sanoswiss uab - metformiin+vildagliptiin - õhukese polümeerikattega tablett - 850mg+50mg 60tk; 850mg+50mg 30tk; 850mg+50mg 10tk; 850mg+50mg 56tk; 850mg+50mg 120tk; 850mg+50mg 180tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited - vildagliptiin - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Euroopa Liit - eesti - EMA (European Medicines Agency)

avimedical b.v. - itraconazole - antimycotics süsteemseks kasutamiseks, triasooli derivaadid, itraconazole - lind - ravi aspergillosis ja kandidoos kaaslane linnud,.

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited - vildagliptiin - suhkurtõbi, tüüp 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 erinevate kombinatsioonide kohta kättesaadavate andmete osas).

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited - vildagliptiin - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 erinevate kombinatsioonide kohta kättesaadavate andmete osas).